Paclitaxel (NSC 125973) - 10mM in DMSO, high purity , CAS No.33069-62-4(DMSO), Agonist of Pregnane X receptor;Agonist of TLR4;Inhibitor of tubulin beta class I
Paclitaxel (NSC 125973) - 10mM in DMSO, high purity , CAS No.33069-62-4(DMSO), Agonist of Pregnane X receptor;Agonist of TLR4;Inhibitor of tubulin beta class I
Paclitaxel (NSC 125973, PTX, Taxol, Onxal, Abraxane) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Storage Temp
Store at -80°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Grade
Moligand™
Action Type
AGONIST, INHIBITOR
Mechanism of action
Agonist of Pregnane X receptor;Agonist of TLR4;Inhibitor of tubulin beta class I
Product Description
Information
Paclitaxel (NSC 125973, PTX, Taxol, Onxal, Abraxane) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells. In vitro
Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells.
In vivo
The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. Cell Data
cell lines：HT29, SW620 and MDA-MB-231 cells
Concentrations：0.1-100 pM
Incubation Time：72 hours
Powder Purity:≥98%
Associated Targets(Human)
SLCO1B1TchemSolute carrier organic anion transporter family member 1B1 (2 Activities)
